Opus Genetics reported a net loss of $8.2 million for the first quarter of 2025, compared to a net loss of $7.1 million in the same period last year. Revenue increased to $4.4 million, primarily from a collaboration agreement. The company ended the quarter with $41.8 million in cash and cash equivalents.

Opus Genetics reported a net loss of $7.5 million for the quarter ended September 30, 2024, or $(0.29) per basic and diluted share, compared to a net income of $5.6 million for the third quarter of 2023. The company's cash and cash equivalents were approximately $37 million as of September 30, 2024, expected to fund operations into 2026.

Ocuphire Pharma reported a net loss of $7.8 million, or $(0.30) per share, for the second quarter ended June 30, 2024. The company's cash and cash equivalents totaled $41.4 million as of June 30, 2024, which is expected to fund operations into mid-2025. License and collaborations revenue was $1.1 million for the quarter.

Ocuphire Pharma reported a net loss of $7.1 million for Q1 2024, with license and collaborations revenue of $1.7 million. The company's cash and cash equivalents totaled $47.2 million as of March 31, 2024, expected to fund operations into mid-2025. Viatris launched RYZUMVI™ in April 2024, leading to Ocuphire's first royalty payment.

Ocuphire Pharma reported financial results for the fourth quarter and full year ended December 31, 2023. The company had cash and cash equivalents of approximately $50.5 million as of December 31, 2023, which is expected to fund operations into mid-2025. License and collaboration revenue was $1.7 million for the quarter, and the net loss was $4.8 million, or ($0.21) per basic and diluted share.

Ocuphire Pharma reported a successful third quarter of 2023, marked by FDA approval of RYZUMVI™, a $10 million milestone payment from Viatris, and positive clinical trial results for APX3330 and phentolamine ophthalmic solution. The company's cash reserves are expected to fund operations into 2025.

Ocuphire Pharma reported license and collaborations revenue of $3.7 million for the second quarter of 2023. The company's cash and cash equivalents were approximately $40.0 million as of June 30, 2023, which is expected to fund operations into 2025. The net loss for the quarter was $5.0 million, or ($0.24) per share.

Ocuphire Pharma reported license and collaborations revenue of $1.7 million for Q1 2023, derived from reimbursement of research and development services under the Nyxol License Agreement. The company's cash and cash equivalents were approximately $39 million, sufficient to fund operations into 2025. Net loss for the quarter was $5.8 million, or ($0.28) per share.

Ocuphire Pharma reported a net income of $33.9 million for the fourth quarter ended December 31, 2022, compared to a net loss of $6.3 million for the same period in 2021. The company's cash and cash equivalents totaled $42.6 million as of December 31, 2022, and they anticipate this will fund operations into 2025. License and collaborations revenue was $39.9 million for the quarter.

Ocuphire Pharma reported a net loss of $4.5 million for Q3 2022. The company's cash and cash equivalents totaled $13.9 million as of September 30, 2022, which is expected to fund operations into Q4 2023. The company is on track for NDA submission for Nyxol for reversal of mydriasis in Q4 2022 and topline data from ZETA-1 Phase 2b trial of oral APX3330 is expected in early 2023.

Ocuphire Pharma reported a net loss of $4.9 million for Q2 2022, with cash and cash equivalents totaling $17.0 million as of June 30, 2022. The company is focused on a late 2022 NDA filing for Nyxol in reversal of mydriasis and anticipates potential approval in 2023.

Ocuphire Pharma reported a net loss of $6.6 million, or $0.35 per share, for Q1 2022. As of March 31, 2022, the company's cash and cash equivalents totaled $19.2 million, expected to fund operations into Q2 2023.

Ocuphire Pharma reported its Q4 and full year 2021 financial results, highlighting the completion of patient enrollment in four late-stage trials and anticipating multiple late-stage clinical trial data catalysts in 2022. The company's cash and cash equivalents were approximately $24.5 million as of December 31, 2021, which is expected to fund operations into the second quarter of 2023.

Ocuphire Pharma reported third-quarter results, highlighting the progress of its late-stage clinical programs, including upcoming Phase 3 trials for Nyxol® Eye Drops and data readouts expected in early 2022. The company's cash runway extends into late 2022.

Ocuphire Pharma reported a productive second quarter of 2021, marked by clinical trial successes, key data presentations, and strengthened IP protection for Nyxol. The company's cash balance reached $24.2 million, expected to provide runway into late 2022.

Ocuphire Pharma announced positive top-line results from the pivotal MIRA-2 Phase 3 trial for Nyxol eye drops in reversal of mydriasis. The company also initiated multiple Phase 2 and 3 clinical trials and is progressing with its second product candidate, APX3330, in Diabetic Retinopathy.

Ocuphire Pharma reported a net loss of $24.6 million for the year ended December 31, 2020. The company's cash and cash equivalents totaled approximately $16.4 million. Key milestones included becoming a Nasdaq-listed company and advancing its Nyxol® and APX3330 programs.